[June 20, 2016] |
|
Dynamics Within Industry-Academia Partnerships Changing - Research and Markets
Research and Markets has announced the addition of the "Cancer
Drug News Issue 666" report to their offering.
The favourable terms for academia in the deal highlight a shift in
dynamics in industry-academia partnership. As more big pharma companies
seek to leverage open innovation to drive lower cost, faster and more
flexible R&D, competition for top institutions will increase. We expect
a move away from academia being seen as just a provider of early
research for the industry, towards more equally weighted partnerships.
Key Topics Covered:
-
Dynamics Within Industry-Academia Partnerships Changing
-
CHMP Adopts Positive Opinion On Empliciti For MM
-
Kyprolis Approvd For Multiple Myeloma In Canada
-
Bendeka Available In US
-
Venetoclax Receives FDA Breakthrough Therapy Designation For AML
-
Cabozantinib Will Encounter Toughening Market Environment Despite
Swift (News - Alert) Entry
-
Tookad Filed For Approval In Mexico Following Positive Phase III
Results In PCA
-
AstraZeneca's Lynparza Drive Will Secure Sustained Revenue Growth
-
Stelba Submits Tookad MAA To EMA (News - Alert)
-
Jakafi Phase II Substudy Stopped Early Due To Insufficient Efficacy
-
Halozyme Raises Funds To Continue Oncology Development
-
Sun Launches Imatinib Mesylate In US
-
HUYA Grants Exclusive Licence For HBI-8000 To Eisai
-
Aduro Receives Clinical Development Milestone Payments From Janssen
-
FDA Approves Eisai's Halaven For Advanced Liposarcoma
-
Adicet Raises Funds; Acquires Applied Immune Technologies
-
Spectrum (News - Alert) Initiates SPI-2012 Phase III Trial Chemotherapy-Induced
Neutropenia In BC
-
Strong Oncology Profile To Support 2016 Growth
For more information visit http://www.researchandmarkets.com/research/mkptcr/cancer_drug_news
View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005637/en/
[ Back To TMCnet.com's Homepage ]
|